Table 2. Clinical characteristics, management and outcomes of patients with CMV reactivation.

|  |  |
| --- | --- |
| Modality | Number (%) |
| CMV reactivation  Yes  No | 37 (17.6%)  173 (82.4%) |
| Time to reactivation, days  Median (range) | 31 (21-54) |
| Anti-CMV therapy  Ganciclovir  Valganciclovir  Foscarnet | 26 (70.3%)  9 (24.3%)  2 (5.4%) |
| Treatment-related complications  Pancytopenia  Neutropenia  Thrombocytopenia  Renal impairment  Hypomagnesaemia  Hypocalcemia  Other complications | 3 (8.1%)  5 (13.5%)  4 (10.8%)  2 (5.4%)  5 (13.5%)  1 (2.7%)  3 (8.1%) |
| Duration of anti-CMV therapy, days  Induction therapy, median (range)  Maintenance therapy, median (range) | 8 (4-15)  10 (6-16) |
| Development of CMV disease  Yes  No | 0 (0%)  37 (100%) |
| Mortality  Overall  Day 100 | 11 (29.7%)  0 |